Mark V. Roeder

Silicon Valley
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA
 
 

Mark Roeder represents life sciences and technology companies at all stages of their life cycle, as well as the institutions that finance them. Mr. Roeder advises companies on strategic transactions and corporate governance matters. Specifically, he counsels clients on:

  • Initial Public Offerings (IPOs)
  • Secondary and follow-on equity public offerings
  • Strategic buy-side and sell-side mergers and acquisitions
  • Venture capital financings
  • Convertible debt offerings

He also provides general company representation, advising executives and boards on topics such as:

  • Corporate governance matters
  • Fiduciary duties
  • Securities law compliance
  • Executive compensation matters
  • Shareholder activism and defense

Mr. Roeder frequently speaks on the IPO process and corporate governance matters.

Mr. Roeder's representative transactions include:

Life Sciences IPOs and Follow-on Equity Offerings – Company Representation
  • Ardelyx – US$60 million IPO and several follow-on equity offerings raising nearly US$350 million
  • Ascendis Pharma – US$124 million IPO and several follow-on equity public offerings raising more than US$900 million
  • CytomX Therapeutics – US$142 million follow-on equity public offering
  • Intermune –convertible notes offerings raising US$276 million, and several follow-on equity public offerings US$860 million
  • KYTHERA Biopharmaceuticals – US$80 million IPO and US$133 million follow-on offering
  • Mirna Therapeutics – US$49 million IPO
  • OncoMed Pharmaceuticals – US$87 million IPO  and US$51 million follow-on equity public offering
  • Relypsa – US$78 million IPO and multiple follow-on equity public offerings raising nearly US$300 million
  • UNITY Biotechnology – US$85 million IPO
Life Sciences IPOs and Follow-on Equity Offerings – Underwriters Representation
  • Aduro Biotech – US$136 million IPO
  • Alios BioPharma – US$1.75 billion sale to Johnson & Johnson
  • AveXis – several follow-on equity public offerings raising nearly US$750 million
  • CytomX Therapeutics – US$92 million IPO
Life Sciences – M&A Transactions
  • CV Therapeutics – US$1.5 billion sale to Gilead Sciences following a successful defense against a hostile bid by Astellas Pharma
  • DVS Sciences – US$208 million sale to Fluidigm
  • Envoy Therapeutics – US$140 million sale to Takeda Pharmaceutical
  • KYTHERA Biopharmaceuticals – US$2.1 billion sale to Allergan
  • Menlo Therapeutics – US$120 million IPO
  • Modernizing Medicines – US$58 million acquisition of gMed
  • Odonate Therapeutics – US$160 million initial public
  • Pearl Therapeutics – US$1.15 billion sale to AstraZeneca
  • Relypsa – US$1.53 billion sale to Galenica Group
Technology IPOs and Follow-on Offerings – Company Representation
  • Integrated Device Technology – US$374 million convertible notes offering
  • Mellanox Technologies – US$117 million IPO and follow-on public equity offering raising nearly US$100 million
Technology – M&A Transactions
  • Greenplum – sale to EMC (confidential terms)
  • Integrated Device Technology – US$1.7 billion merger with Integrated Circuit Systems
  • Integrated Device Technology – US$7.1 billion sale to Reneasas
  • Mellanox Technologies – US$6.9 billion sale to Nvidia, US$811 million purchase of EZ Chip, US$82 million purchase of Kotura, US$218 million purchase of Voltaire, and US$48 million purchase of IPtronics
  • Netli – US$170 million sale to Akamai Technologies
Venture Financings
  • Lead Investors’ counsel in hundreds of venture financings, including investments in: Carta, Segment.io, Lucid Software, Duo Security, Mulesoft, Verkada, Cloudera, ROBLOX, Zulily, Tableau Software, and Box

 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.